---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056870"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:40:44.580611+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q1 net loss $29.5M; cash $450M; NKX019 lupus dosing on track

## Summary
- Cash, equivalents and investments of $450.0M at March 31, 2024, including $240.1M from March offering.
- Net loss of $29.5M ($0.58 per share) for Q1 2024; R&D expense $25.2M, G&A $7.5M.
- First patient dosing with NKX019 in lupus nephritis expected H1 2024; IND cleared 4Q2023.
- Preliminary NKX019 compressed dosing data in NHL expected mid-2024; 4/4 re-treated patients achieved CR.
- Cash runway expected to fund operations into late 2027.

## SEC filing metadata
- accession: 0000950170-24-056870
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/0000950170-24-056870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/nktx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056870
- JSON: https://secwatch.observer/filing/0000950170-24-056870.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056870.txt

## Key facts
- Earnings Releases
  Nkarta, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024., EPS $0.58 per basic and diluted share.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024.
  - EPS: $0.58 per basic and diluted share
  - Result: reported results
  source text: Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/0000950170-24-056870-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.